Table of Content

1. Introduction



2. Research Methodology



3. Executive Summary



4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges


5. United States Liquid Biopsy Market



6. Market Share
6.1 By Cancer Types
6.2 By Product
6.3 By Biomarkers
6.4 By Application
6.5 By Sample Types
6.6 By End User


7. Cancer Types
7.1 Lung Cancer
7.2 Breast Cancer
7.3 Colorectal Cancer
7.4 Prostate Cancer
7.5 Liver Cancer
7.6 Other Cancer


8. Products
8.1 Kits & Reagents
8.2 Platforms & Instruments
8.3 Services


9. Biomarkers
9.1 Circulating Tumor Cells (CTCs)
9.2 Circulating Tumor DNA (ctDNA)
9.3 Extracellular Vesicles (EVs)
9.4 Other Biomarker Types


10. Application
10.1 Early Diagnosis
10.2 Patient Monitoring
10.3 Recurrence Monitoring


11. Sample Types
11.1 Blood
11.2 Urine
11.3 Others


12. End User
12.1 Hospitals & Laboratories
12.2 Governments & Academic Research Centers


13. Porter’s Five Forces Analysis
13.1 Bargaining Power of Buyers
13.2 Bargaining Power of Suppliers
13.3 Degree of Competition
13.4 Threat of New Entrants
13.5 Threat of Substitutes


14. SWOT Analysis
14.1 Strength
14.2 Weakness
14.3 Opportunity
14.4 Threats


15. Key Players Analysis
15.1 Thermo Fisher Scientific Inc.
15.1.1 Overview
15.1.2 Recent Development
15.1.3 Revenue

15.2 Roche Diagnostics
15.2.1 Overview
15.2.2 Recent Development
15.2.3 Revenue

15.3 Bio-Rad Laboratories Inc.
15.3.1 Overview
15.3.2 Recent Development
15.3.3 Revenue

15.4 Biocept, Inc.
15.4.1 Overview
15.4.2 Recent Development
15.4.3 Revenue

15.5 Biocartis
15.5.1 Overview
15.5.2 Recent Development
15.5.3 Revenue

15.6 Myriad Genetics, Inc.
15.6.1 Overview
15.6.2 Recent Development
15.6.3 Revenue

15.7 Exact Sciences (Genomic Health)
15.7.1 Overview
15.7.2 Recent Development
15.7.3 Revenue

15.8 NeoGenomics Laboratories
15.8.1 Overview
15.8.2 Recent Development
15.8.3 Revenue

15.9 Quest Diagnostic Inc.
15.9.1 Overview
15.9.2 Recent Development
15.9.3 Revenue



List of Figures

0

List of Tables

0